Literature DB >> 27056994

Hydroxyurea for abnormal TCDs: safe to switch?

Patrick T McGann1.   

Abstract

In this issue of Blood, Bernaudin et al report that chronic red blood cell transfusions can be safely replaced with hydroxyurea therapy or bone marrow transplantation for a cohort of children with sickle cell anemia (SCA) and abnormal transcranial Doppler (TCD) velocities. These data nicely complement the recently published results from the phase 3 multicenter TCD With Transfusions Changing to Hydroxyurea (TWiTCH) study and suggest that it may be safe to carefully transition a subset of patients from chronic transfusions to hydroxyurea therapy.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27056994      PMCID： PMC4825411          DOI： 10.1182/blood-2016-02-699074

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  6 in total

1.  Changing ethnic disparity in ischemic stroke mortality in US children after the STOP trial.

Authors:  Laura L Lehman; Heather J Fullerton
Journal:  JAMA Pediatr       Date:  2013-08-01       Impact factor: 16.193

2.  Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities.

Authors:  Françoise Bernaudin; Suzanne Verlhac; Cécile Arnaud; Annie Kamdem; Isabelle Hau; Emmanuella Leveillé; Manuela Vasile; Florence Kasbi; Fouad Madhi; Christine Fourmaux; Sandra Biscardi; Eliane Gluckman; Gérard Socié; Jean-Hugues Dalle; Ralph Epaud; Corinne Pondarré
Journal:  Blood       Date:  2016-02-05       Impact factor: 22.113

3.  Cerebrovascular accidents in sickle cell disease: rates and risk factors.

Authors:  K Ohene-Frempong; S J Weiner; L A Sleeper; S T Miller; S Embury; J W Moohr; D L Wethers; C H Pegelow; F M Gill
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

4.  The use of transcranial ultrasonography to predict stroke in sickle cell disease.

Authors:  R Adams; V McKie; F Nichols; E Carl; D L Zhang; K McKie; R Figueroa; M Litaker; W Thompson; D Hess
Journal:  N Engl J Med       Date:  1992-02-27       Impact factor: 91.245

5.  Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.

Authors:  R J Adams; V C McKie; L Hsu; B Files; E Vichinsky; C Pegelow; M Abboud; D Gallagher; A Kutlar; F T Nichols; D R Bonds; D Brambilla
Journal:  N Engl J Med       Date:  1998-07-02       Impact factor: 91.245

6.  Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

Authors:  Russell E Ware; Barry R Davis; William H Schultz; R Clark Brown; Banu Aygun; Sharada Sarnaik; Isaac Odame; Beng Fuh; Alex George; William Owen; Lori Luchtman-Jones; Zora R Rogers; Lee Hilliard; Cynthia Gauger; Connie Piccone; Margaret T Lee; Janet L Kwiatkowski; Sherron Jackson; Scott T Miller; Carla Roberts; Matthew M Heeney; Theodosia A Kalfa; Stephen Nelson; Hamayun Imran; Kerri Nottage; Ofelia Alvarez; Melissa Rhodes; Alexis A Thompson; Jennifer A Rothman; Kathleen J Helton; Donna Roberts; Jamie Coleman; Melanie J Bonner; Abdullah Kutlar; Niren Patel; John Wood; Linda Piller; Peng Wei; Judy Luden; Nicole A Mortier; Susan E Stuber; Naomi L C Luban; Alan R Cohen; Sara Pressel; Robert J Adams
Journal:  Lancet       Date:  2015-12-06       Impact factor: 79.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.